DNA methylation at CHRNA7 promoter region

DNA methylation at the CHRNA7 promoter region refers to the covalent modification of cytosine residues (particularly at CpG sites) with methyl groups within the promoter region of the CHRNA7 gene. This modification acts as an epigenetic silencing mechanism, reducing or blocking the transcription of the CHRNA7 gene and thereby decreasing expression of the α7 nicotinic acetylcholine receptor (α7 nAChR). Reduced α7 nAChR expression is implicated in schizophrenia, cognitive impairment, and other neuropsychiatric conditions. Both genetic variation and environmental factors can modulate promoter methylation, and certain drugs (e.g., valproate, DNA methyltransferase inhibitors) can reduce methylation, restore gene expression, and potentially improve cognitive or psychiatric symptoms. However, as methylation is a regulatory mechanism and not a canonical drug target, therapies act indirectly by changing the chromatin state rather than binding a specific protein or molecular entity[1][5][2][3][7].

Other names

Methylation of CHRNA7 promoterCHRNA7 promoter CpG methylationEpigenetic silencing of CHRNA7

Inhibition of DNA methyltransferases (leading to demethylation, gene activation) Modulation of methyl group metabolism (methionine deprivation reduces methylation) Inhibition of Ras signaling (lonafarnib, through c-Jun-JNK-DNMT pathway, decreases methylation)